The National Institute for Health and Care Excellence

NICE: backing the healthtech that changes lives

Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
The National Institute for Health and Care Excellence

Faster, fairer access to HealthTech under new national programme

The 10 Year Health Plan set out how the government will address the long-standing challenge that cutting-edge HealthTech is not being used in the NHS , or is only available to patients in some parts ...
The National Institute for Health and Care Excellence

NICE says paperclip-sized sensor could help thousands monitor heart condition from home

A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before ...
The National Institute for Health and Care Excellence

Simple home test prevents thousands of unnecessary bowel cancer referrals

The faecal immunochemical test (FIT) detects small amounts of blood in poo, which can be a sign of bowel cancer. Bowel cancer is the second biggest cancer killer in the UK, affecting the large bowel ...
National Institute for Health and Care Excellence

Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer

There is a simple discount patient access scheme for nivolumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management

This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, ...
National Institute for Health and Care Excellence

Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over

There is a simple discount patient access scheme for idebenone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UK.pas@gsk.com ...
National Institute for Health and Care Excellence

Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment

There is a simple discount patient access scheme for elacestrant. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment

We have moved Health technology evaluation 20 to become HealthTech guidance 739. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...
National Institute for Health and Care Excellence

Tirzepatide for managing overweight and obesity

A commercial access agreement was added to this guidance and the price list for tirzepatide was updated. Next review: This guidance will be reviewed if there is new evidence that is likely to change ...